Active Pharmaceutical Ingredient (API) in Russia: Production, Market and Forecast

This review represents the first edition of a study on the Russian market for active pharmaceutical ingredients (API).

The objective of this review is to provide investors with an objective, comprehensive assessment of the Russian API market to facilitate informed investment decision-making—including evaluating the feasibility of market entry, selecting product niches, determining business models and localization formats, and identifying key risks along with strategies for their mitigation (i.e., measures designed to reduce the adverse consequences of a specific event, process, or phenomenon).

The review aims to:

1. Assess the size, dynamics, and structure of the API market in both physical and monetary terms; identify trends in localization and import substitution; and determine the respective shares of domestic production and imports across various segments.

2. Analyze investment projects and production capacities—both existing and announced—including estimates of capital expenditure (CAPEX), launch timelines, target production volumes, and technological solutions; and develop a "portfolio of opportunities" for investors.

3. Evaluate the structure of imports and exports; identify critical dependencies regarding specific APIs and intermediates; and analyze supply chain risks and potential diversification strategies.

4. Develop a financial model for API production, covering cost structures, price dynamics, profit margins by business model type, project profitability and payback periods, and the sensitivity of the internal rate of return (IRR) to key parameters.

5. Assess the technological and raw-material base—including the maturity of technological platforms, the extent to which raw materials and equipment are localized, and the available human capital—while identifying potential technological risks and corresponding solutions. 6. Identify key risks and barriers—technological, regulatory, financial, human resource-related, macroeconomic, and those stemming from sanctions—including an assessment of their probability, impact on the internal rate of return (IRR), and potential mitigation tools.

7. Determine growth drivers and promising market niches, such as areas for state support, the development of cooperation and industrial clusters, innovation, and technology transfer; formulate quantitative development scenarios through 2030.

8. Conduct a competitive analysis—compare major manufacturers based on financial, operational, and technological criteria; perform a SWOT analysis of the industry; and evaluate Russia’s positioning in both domestic and international markets.

9. Formulate recommendations for investors, covering priority product niches, optimal localization models, risk-mitigation measures, and the role of state support.

Object of study: The Russian market for active pharmaceutical ingredients (APIs), encompassing the production, import, export, and consumption of these substances within the Russian Federation and the Eurasian Economic Union (EAEU).

Subject of study: The status, dynamics, structure, economics, technological base, competitive landscape, and development prospects of the API market in Russia, with a focus on assessing its investment attractiveness.

Geographic scope: The Russian Federation; the EAEU context (Belarus, Kazakhstan, Armenia, Kyrgyzstan); and key partner countries (China, India, and the EU).

Types of synthesis: Chemical synthesis (batch and continuous); biotechnological synthesis (monoclonal antibodies, recombinant proteins, insulins, coagulation factors, vaccines, CAR-T, mRNA); and extraction (from plant, animal, or mineral sources).

Product scope: Active pharmaceutical ingredients (APIs). Intermediates (synthesis intermediates), key starting materials (KSMs), and excipients—specifically those that impact the economics of active pharmaceutical ingredient (API) production.

Value chain: from basic petrochemical feedstocks → intermediates → APIs → finished dosage forms—with a focus on the API synthesis stage as the critical point for investment value.

Time horizon: retrospective: 2020–2025 (statistical data); current status: 2026; forecast: 2027–2030.

Investment focus: projects for the full-cycle localization of API production (substance synthesis + finished dosage form); contract development and manufacturing organizations (CDMOs); localization of intermediates; and biotechnological substances.

Methodology

This note was prepared using a comprehensive approach that incorporates:

1. Statistical analysis—processing data from Rosstat (industrial production indices, output volumes), the Federal Customs Service (import/export customs statistics), the Ministry of Industry and Trade (registry of special investment contracts, lists of essential medicines [VED/EDL], and the localization scoring system), the Federal Tax Service (industry-specific profitability), and publicly available data from the Eurasian Economic Commission (analysis of the substance market within the EAEU).

2. Analysis of industry reporting – reports and presentations from public and private pharmaceutical companies (PJSC Promomed, PJSC Ozon Pharmaceuticals, JSC Biocad, JSC Pharmasyntez, JSC Active Component, JSC R-Pharm); analytical reviews from investment banks (Alfa-Bank, Sber CIB) and rating agencies (Expert RA); and reports from industry-focused analytical firms (DSM Group, RNC Pharma, Bexordia Lab, OKS Labs, Cursor).

3. Analysis of the regulatory framework – including federal laws (Federal Law No. 61-FZ "On the Circulation of Medicines," Federal Law No. 304-FZ on registration, and Federal Law No. 324-FZ on a differentiated approach to GMP inspections), Government Decrees (Decree No. 1392 on the points-based system, Decree No. 719 on the Chamber of Commerce and Industry registry, and Decree No. 441 on simplified registration procedures), decisions of the Eurasian Economic Commission Council (Decision No. 77 on EAEU GMP rules), and strategic documents (the "Pharma-2030" Strategy and the "New Health-Preserving Technologies" national project).

4. Analysis of investment projects – data on announced and ongoing projects (CAPEX, timelines, production capacities, and funding sources) gathered from company press releases, statements by the Ministry of Industry and Trade, the Industrial Development Fund (IDF), VEB.RF, and Special Economic Zones (SEZs), as well as materials from the St. Petersburg International Economic Forum (SPIEF) and industry-specific forums (such as Bioprom-2026 and PharmTech).

5. Expert assessment and modeling – development of a financial model for a representative investment project (covering cost structure, CAPEX, OPEX, IRR, NPV, and sensitivity analysis), SWOT analysis, scenario forecasting (base, optimistic, and pessimistic scenarios through 2030), and a risk matrix evaluating the probability and impact of potential risks.

6. Comparative analysis – benchmarking of Russian manufacturers based on financial, operational, and technological metrics; comparisons with global leaders (in China, India, and the EU) regarding production costs, scale, and competitive landscape; and the ranking of CDMO (Contract Development and Manufacturing Organization) facilities.

The sources of information used include data from the statistical committees of EAEU member states (such as Rosstat, the National Statistical Committee of the Republic of Belarus, and the Bureau of National Statistics of the Agency for Strategic Planning and Reforms of the Republic of Kazakhstan); international databases (UNdata, the World Bank, Eurostat); international and European trade data (UN Comtrade, Trade Map); records from the Federal Customs Service of the Russian Federation (up to 2022); the Unified Information System in the Sphere of Procurement; railway transport statistics; the SBIS database; data from specialized foreign firms; annual and quarterly reports from securities issuers; industry and regional press; conference materials; the websites of manufacturers and consumers of the products under study; scientific and technical literature (e.g., eLibrary); the FIPS patent database; the Infomine database; and others.

Data Limitations

When using this review, investors should take the following limitations into account:

1. Partial lack of transparency in corporate reporting. A significant number of Russian active pharmaceutical ingredient (API) manufacturers are private entities (joint-stock companies or limited liability companies) that do not disclose detailed financial statements. Data regarding revenue, profit, capital expenditure (CAPEX), and production capacity are derived from open sources (the Unified State Register of Legal Entities, SPARK, Rusprofile, and industry rankings) and may differ from actual figures. Certain key metrics—such as production capacity for specific international nonproprietary names (INNs), capacity utilization rates, and portfolio composition—are based on expert estimates and company press releases.

2. Variations in the classification of APIs and intermediates. In customs statistics and industry reporting, the distinctions between APIs, intermediates, and fine chemicals are not always clearly defined. The Commodity Nomenclature for Foreign Economic Activity (TN VED) does not categorize pharmaceutical substances as a distinct group; instead, they are subsumed under general codes for chemical products. This leads to discrepancies of 10–20% in market size estimates across various sources (Rosstat, the Federal Customs Service, and industry agencies).

3. Differences in methodologies for assessing localization. Prior to the introduction of the points-based system (effective July 1, 2026), the term "full-cycle production" lacked a universal definition. In the List of Essential and Vital Medicines (VEDL), a drug could be classified as "full-cycle" if a domestic substance was listed in its registration certificate—even if it was actually manufactured using an imported substance, in cases where both domestic and imported substances were included in the same registration certificate. Of the 2,016 trade names classified as "full-cycle," 1,020 (51%) represent "genuine full-cycle" production, while 996 (49%) are "conditional"—meaning the registration certificate lists both domestic and imported substances.

4. Volatility in currency exchange rates and logistics costs. The financial model presented in this review is based on conditions projected for 2024–2026 (an exchange rate of 80–95 RUB/USD and logistics costs at 130–160% of pre-pandemic levels). Significant shifts in exchange rates, transportation costs, or customs duties could substantially impact production costs and profit margins. Regarding the sensitivity of the Internal Rate of Return (IRR) to exchange rates: a fluctuation of 10 RUB/USD results in a 3–5 percentage point change in the IRR.

5. The dynamic nature of the regulatory environment. The regulatory landscape of the Russian pharmaceutical market is undergoing a phase of active transformation, characterized by several key developments: a points-based localization system (effective July 1, 2026), the "second-is-excluded" (*vtoroy lishniy*) mechanism (effective September 1, 2025 / December 1, 2026), a product traceability system (effective July 1, 2026), and a transition period for bringing national registration dossiers into compliance with EAEU requirements (ending January 1, 2027). Specific parameters may be refined, and timelines may be adjusted; therefore, investors are advised to monitor the latest versions of the relevant regulatory acts.

6. Limited data on the biotechnology segment. Biotechnological substances (monoclonal antibodies, recombinant proteins) represent the fastest-growing yet least transparent segment of the market. Manufacturers do not disclose production volumes in kilograms, capacities for specific platforms, or capacity utilization rates. Market estimates are based on data for finished pharmaceutical products and expert-derived calculations.

7. Predictive nature of scenarios. Development scenarios through 2030 (base, optimistic, and pessimistic) are based on the extrapolation of current trends and the assumption that key regulatory and macroeconomic parameters will remain constant. Significant shifts in the geopolitical landscape, the sanctions regime, or the trade policies of China and India could cause actual outcomes to deviate from these projections.

The report consists of an introduction, 9 sections, and a conclusion; it spans 195 pages and includes 121 tables.

Section 1: Regulatory and strategic framework (regulatory environment, support measures, the "points-based" system, the "second-is-out" rule, and SPIK 2.0 [Special Investment Contracts 2.0]).

Section 2: Market size, dynamics, and structure (key metrics for investors: market capacity, import share, and segmentation by synthesis type and therapeutic group).

Section 3: Production and investment projects (portfolio of opportunities: trends, geography, key players, ongoing and announced projects, and localization scenarios).

Section 4: Imports, exports, and supply chains (risks and opportunities: import structure by country, critical dependencies, export potential, and logistics- or currency-related risks).

Section 5: Production Economics and Financial Model (production costs, margins, payback period, IRR, sensitivity analysis, and the impact of vertical integration).

Section 6: Technological and Raw Material Base (technological platforms, raw material supply chains, equipment, and human resources).

Section 7: Risks and Barriers (technological, regulatory, financial, human resource-related, macroeconomic, and sanctions-related; risk matrix with an assessment of the impact on IRR).

Section 8: Drivers and Promising Niches (entry points for investors: government support, cooperation, innovation, high-potential areas, and scenarios through 2030).

Section 9: Competitive Analysis and Positioning (comparative table of producers, SWOT analysis, positioning in domestic and international markets, and an investment attractiveness map by segment).

Conclusion: Key findings, assessment of progress toward import substitution goals, and recommendations for investors.

Appendices: Tables, charts, glossary, and a list of sources.